Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 19/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26683256 | 1.00 | SLC6A3 (0.60) | SLC6A3SLC6A4SLC6A2CHRM2CHRM4 | |
| SCHEMBL6521453 | 0.86 | SLC6A3 (0.56) | SLC6A3SLC6A4 | |
| SCHEMBL7321371 | 0.85 | SLC6A3 (0.67) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL3418076 | 0.85 | SLC6A3 (0.67) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL6515132 | 0.81 | SLC6A3 (0.66) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL6762602 | 0.70 | SLC6A3 (1.00) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL6767667 | 0.69 | SLC6A3 (0.76) | SLC6A3SLC6A4 | |
| SCHEMBL26683852 | 0.69 | SLC6A3 (1.00) | SLC6A3SLC6A4 | |
| SCHEMBL4138870 | 0.68 | SLC6A3 (0.39) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL4147504 | 0.68 | SLC6A3 (0.39) | SLC6A3SLC6A4SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023219199-A1 | MANUFACTURING METHOD FOR FP-CIT PRECURSOR, AND MANUFACTURING METHOD FOR [18F]FP-CIT USING FP-CIT PRECURSOR MANUFACTURED THEREBY | (주)듀켐바이오 | 2023-11-16 | — | — | WO | disclosed |